OxSonics® proprietary SonoTran® Platform comprises injectable SonoTran Particles and a portable ultrasound SonoTran System. The Platform is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby potentially increasing the efficacy of these agents when used to treat solid tumour cancers. OxSonics, based in Oxford will start its first clinical trial in H1 2021 with its SonoTran Platform in metastatic colorectal cancer patients..
OxSonics applied to the M4R programme to access NPL’s expertise, to measure the number of SonoTran Particles per unit mass of product. The work that NPL conducted also confirmed the consistency of the number of SonoTran Particles across different batches. The data delivered by NPL informs OxSonics on the concentration of SonoTran Particles it needs to aim for in future enhancements of its particle formulations.
